Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Realheart Changes From Quarterly to Biannual Financial Reporting

Scandinavian Real Heart

Västerås, Sweden, June 27, 2025 – Scandinavian Real Heart AB (publ) announces today that the company is shifting from issuing financial reports once per quarter to semi-annual reporting. The change is made as a strategic decision intended to free up time for the company’s management to be dedicated to the development of Realheart® TAH and increase cost efficiency. Consequently, the financial reporting will comprise three reports: one for the first half-year, one for the second half-year/full year, and an annual report.

The decision to shift from quarterly to biannual reporting follows the company’s internal overview and is an initiative to increase product development efficiency and decrease company costs. The transition is made in accordance with marketplace rules (First North Growth Market Rulebook, chapter 4.4). The company will continue to update the market via its official channels, including press releases and social media, on notable events connected to the company’s activities. As previously communicated, all future communications from Realheart will be in English.

For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21 
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

Attachments
Realheart Changes From Quarterly to Biannual Financial Reporting

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.